LBRX Stock Analysis: Buy, Sell, or Hold?
LBRX - LB Pharmaceuticals Inc Common Stock
$33.43
1.54 (4.83%)
▲
5d:
+7.84%
30d:
+23.72%
90d:
+34.74%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When LBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: LBRX is 7.0% above its trading range ($31.23). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: LBRX is 7.0% above its trading range ($31.23). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: LBRX is currently trading at $33.43, which is considered extended relative to its 30-day fair value range of $27.77 to $31.23.
Technical Outlook: Technically, LBRX is in a strong uptrend. The price is approaching resistance at $34.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: LBRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.00 (+34.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LBRX is in a strong uptrend. The price is approaching resistance at $34.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: LBRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.00 (+34.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$27.77 -
$31.23
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+7.0% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.8%)
- BULLISH: Trading 34.6% below Wall St target ($45.00)
- CAUTION: Extended 7.0% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$27.77 -
$31.23
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$29.28
Resistance Level
$34.00
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.45
Wall Street Target
$45.00
(+34.6%)
Share & Embed Analysis
Last updated: July 02, 2026 9:38 PM ET
Data refreshes hourly during market hours. Next update: 10:38 PM
Data refreshes hourly during market hours. Next update: 10:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |